Nanophthalmos 1 (NNO1) Cell Models for Research

Nanophthalmos 1 (NNO1) is a rare genetic eye disorder characterized by a small eye (axial length <20.5 mm) leading to high hyperopia and increased risk of angle-closure glaucoma. The prevalence is estimated at 1 in 10,000 to 1 in 50,000, with autosomal dominant inheritance. Clinical impact includes visual impairment and potential blindness. The disease is caused by mutations in the MFRP gene, which is essential for normal eye development. Early diagnosis and management are critical to prevent complications.

NNO1 serves as a valuable model for studying eye development, particularly the regulation of axial length and refractive error. The disease provides insights into the molecular mechanisms of ocular growth and the pathogenesis of angle-closure glaucoma. Public datasets from NCBI and ClinVar provide mutation information, while functional studies using gene-edited cell models can elucidate the role of MFRP in retinal pigment epithelium and ciliary body. Open questions include the precise signaling pathways and potential therapeutic targets.

• • The primary pathway involves the MFRP gene, which encodes a membrane-type frizzled-related protein involved in Wnt signaling and eye development. Mutations lead to disrupted Wnt signaling, affecting retinal pigment epithelium (RPE) and ciliary body function. Key steps:
• • MFRP interacts with Wnt ligands and receptors.
• • Loss of MFRP function leads to aberrant Wnt signaling.
• • Disrupted signaling affects ocular growth and axial length.
• • Secondary effects include altered extracellular matrix remodeling and inflammation.

Data from ClinVar and literature.

• • Key networks affected in NNO1 include:
• • Wnt signaling: MFRP modulates Wnt pathway, affecting cell proliferation and differentiation.
• • TGF-beta signaling: Involved in extracellular matrix regulation.
• • Retinoic acid signaling: Important for eye development.
• • Key nodes: MFRP, LRP6, FZD4, β-catenin, TGFBR1, SMAD3.

Organoids derived from patient iPSCs can recapitulate retinal development and are useful for studying MFRP function.

• • Mfrp knockout mice: Show reduced axial length and retinal degeneration.
• • Mfrp knock-in mice: Model specific mutations.
• • Zebrafish models: Used for high-throughput screening.
• • PDX models: Limited for eye diseases, but possible for ocular tumors.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific MFRP mutations. For example, a MFRP knockout ARPE-19 cell line can be generated to study loss-of-function effects. Alternatively, a knock-in line with a specific pathogenic mutation (e.g., c.498_499del) can be created to model the disease. These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems for mechanistic studies and drug screening.

Knockout and knock-in lines are used to validate the role of MFRP in eye development. For example, MFRP knockout in ARPE-19 cells can be used to study changes in Wnt signaling and gene expression. Knock-in lines with specific mutations can help determine genotype-phenotype correlations.

Isogenic pairs (wild-type vs. mutant) are ideal for high-throughput screening of compounds that modulate Wnt signaling or rescue MFRP function. Resistance mechanisms can be studied by exposing cells to drugs and selecting for resistant clones.

CRISPR synthetic lethality screens can identify genes that are essential in MFRP-mutant cells but not in wild-type, providing potential therapeutic targets. Such screens can also identify biomarkers for early diagnosis.